Cephalon Appoints Robert W. Grupp, Vice President of Corporate Communications

Apr 19, 2001, 01:00 ET from Cephalon, Inc.

    WEST CHESTER, Pa., April 19 /PRNewswire/ -- Cephalon, Inc. (Nasdaq:   CEPH),
 an international biopharmaceutical company, announced today that
 Robert W. Grupp has joined the company as vice president of corporate
 communications.  Grupp will report to Frank Baldino, Jr., Ph.D., chairman
 and CEO.
     Grupp has more than 21 years of experience in public affairs and
 communications.  Most recently, he served as director of corporate
 communications at Eli Lilly and Company in Indianapolis.  Prior to Lilly, he
 held positions at Dow Corning Corporation and Consumers Energy Company.
 Earlier in his career, he worked as a journalist and editor at daily
 newspapers.
     "Cephalon has grown significantly over the last year, adding two new
 products, expanding its sales force and adding another U.S. site to its
 business," said Dr. Baldino.  "As a fully integrated biopharmaceutical company
 with diverse stakeholders, it is critical to have someone with Bob's
 broad-based communications experience to help us continue to build our
 identity and reputation."
     As head of communications, Grupp will lead the company's public relations
 activities, which include media relations, internal and product
 communications, community relations and issue management.  He also has
 responsibility for investor relations.
     Grupp is an accredited member of the Public Relations Society of America
 (PRSA) and serves on the Council of the International Public Relations
 Association (IPRA).  He is a past chair of the Public Affairs section of the
 Pharmaceutical Research and Manufacturers of America (PhRMA) and is active in
 the Biotechnology Industry Organization (BIO).  Grupp received a Bachelor of
 Science degree in journalism from Southern Illinois University in Carbondale.
 
     Cephalon, Inc., headquartered in West Chester, Pennsylvania, is an
 international biopharmaceutical company dedicated to the discovery,
 development and marketing of products to treat sleep disorders, neurological
 disorders, cancer and pain.  For more information on Cephalon, please visit
 our website at http://www.cephalon.com .
 
 

SOURCE Cephalon, Inc.
    WEST CHESTER, Pa., April 19 /PRNewswire/ -- Cephalon, Inc. (Nasdaq:   CEPH),
 an international biopharmaceutical company, announced today that
 Robert W. Grupp has joined the company as vice president of corporate
 communications.  Grupp will report to Frank Baldino, Jr., Ph.D., chairman
 and CEO.
     Grupp has more than 21 years of experience in public affairs and
 communications.  Most recently, he served as director of corporate
 communications at Eli Lilly and Company in Indianapolis.  Prior to Lilly, he
 held positions at Dow Corning Corporation and Consumers Energy Company.
 Earlier in his career, he worked as a journalist and editor at daily
 newspapers.
     "Cephalon has grown significantly over the last year, adding two new
 products, expanding its sales force and adding another U.S. site to its
 business," said Dr. Baldino.  "As a fully integrated biopharmaceutical company
 with diverse stakeholders, it is critical to have someone with Bob's
 broad-based communications experience to help us continue to build our
 identity and reputation."
     As head of communications, Grupp will lead the company's public relations
 activities, which include media relations, internal and product
 communications, community relations and issue management.  He also has
 responsibility for investor relations.
     Grupp is an accredited member of the Public Relations Society of America
 (PRSA) and serves on the Council of the International Public Relations
 Association (IPRA).  He is a past chair of the Public Affairs section of the
 Pharmaceutical Research and Manufacturers of America (PhRMA) and is active in
 the Biotechnology Industry Organization (BIO).  Grupp received a Bachelor of
 Science degree in journalism from Southern Illinois University in Carbondale.
 
     Cephalon, Inc., headquartered in West Chester, Pennsylvania, is an
 international biopharmaceutical company dedicated to the discovery,
 development and marketing of products to treat sleep disorders, neurological
 disorders, cancer and pain.  For more information on Cephalon, please visit
 our website at http://www.cephalon.com .
 
 SOURCE  Cephalon, Inc.